Clinical Scorecard: The Impact of Anticholinergic Medication Load on the Occurrence of Cardiovascular Events: A Population-Based Analysis
At a Glance
Category
Detail
Condition
Cardiovascular events associated with anticholinergic medication load
Key Mechanisms
Anticholinergic drugs inhibit acetylcholine actions, disrupting cholinergic signaling essential for cardiovascular regulation, potentially causing autonomic dysfunction and increased cardiovascular risk
Target Population
Adults aged 45 years and older without prior major cardiovascular disease, including those with uncomplicated hypertension
Care Setting
General population within a universal healthcare system (Stockholm, Sweden)
Key Highlights
Anticholinergic burden is assessed using the Anticholinergic Cognitive Burden (ACB) scale and cumulative defined daily doses (DDDs) of anticholinergic drugs.
Higher anticholinergic drug exposure is hypothesized to be associated with increased incidence of overall and specific cardiovascular diseases.
Cholinergic signaling plays a critical role in cardiovascular homeostasis; disruption by anticholinergic drugs may impair heart rate and contractility regulation.
Guideline-Based Recommendations
Diagnosis
Assess anticholinergic burden using validated scales such as the ACB scale.
Evaluate cumulative drug exposure through defined daily doses over time.
Management
Minimize use of medications with high anticholinergic properties when possible, especially in older adults.
Consider alternative therapies with lower anticholinergic burden to reduce cardiovascular risk.
Monitoring & Follow-up
Regularly update and monitor anticholinergic drug exposure annually using prescription data.
Monitor for incident cardiovascular events in patients with high anticholinergic burden.
Risks
High anticholinergic burden is linked to increased risk of myocardial infarction, stroke, arrhythmias, conduction disorders, syncope, and cardiovascular death.
Disruption of parasympathetic regulation by anticholinergic drugs may lead to autonomic dysfunction contributing to cardiovascular disease.
Patient & Prescribing Data
Residents aged ≥45 years in Stockholm without prior major cardiovascular disease
Annual cumulative exposure to anticholinergic drugs, measured by DDDs and ACB scores, is critical to evaluate cardiovascular risk; time-updated exposure assessment improves accuracy.
Clinical Best Practices
Use comprehensive medication reviews to identify and quantify anticholinergic burden in patients.
Incorporate time-updated measures of anticholinergic exposure rather than baseline-only assessments.
Recognize the potential cardioprotective role of enhancing cholinergic signaling as a future therapeutic target.
For years, chronic stroke patients heard familiar feedback regarding their ability to regain strength and mobility after ischemic strokes caused upper-extremity deficits.
